621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If the hypothesis is confirmed, this research could establish a novel, more effective treatment paradigm for type 2 diabetes and obesity specifically tailored for postmenopausal women. The synergistic effects of addre…
Understanding the intricate link between gut microbiota composition and semaglutide responsiveness could usher in a new era of personalized obesity treatment. If specific microbial profiles are found to predict who wi…
If this trial demonstrates that Semaglutide can effectively prevent or mitigate metabolic deterioration in patients on antipsychotics, it would represent a significant clinical breakthrough. Schizophrenia patients oft…
If successful, this trial could establish Semaglutide as a crucial adjunctive therapy for men with prostate cancer on ADT, significantly improving their quality of life and long-term health outcomes. The practical tak…
Understanding the pharmacokinetic equivalence of different delivery devices for semaglutide is critical for both clinicians and patients. Consistent drug exposure ensures predictable therapeutic effects, which is vita…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
Comprehensive understanding of GLP-1RA reproductive safety is paramount for women of reproductive age managing obesity or type 2 diabetes. This review underscores the necessity for robust research to establish clear g…
This finding is highly significant for individuals undergoing GLP-1 receptor agonist therapy, as it addresses a major concern: muscle loss. Combining GLP-1RAs with 15-PGDH inhibitors could preserve muscle mass and imp…
This study provides compelling preclinical evidence that semaglutide's neuroprotective actions extend beyond metabolic benefits, directly targeting key AD pathologies. The findings suggest that GLP-1RAs could offer a …
This study holds significant promise for offering a powerful, non-surgical alternative to bariatric surgery for individuals with Type 2 Diabetes and Obesity, particularly within the veteran population. If successful, …
This study is a methodological investigation designed to assess the concordance between real-world data analyses and the original SOUL Diabetes Trial results. As this record describes the study design and objectives r…
The current slow, sequential initiation of therapies for Type 2 Diabetes and CKD means patients often miss out on crucial early protection, leading to disease progression. This pilot study's findings could revolutioni…
Understanding these pharmacokinetic interactions is critical for the safe and effective use of the semaglutide and NNC0480-0389 combination, especially for patients who may also be taking oral contraceptives or pain r…
The development of an oral formulation for a highly effective GLP-1 analogue like semaglutide represents a significant step forward for Type 2 Diabetes management. Oral semaglutide offers enhanced patient convenience …
This planned Phase 1 study is crucial for the development of a potentially more convenient semaglutide formulation. An extended-release semaglutide injectable could significantly improve patient adherence and treatmen…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This research offers a novel and highly promising strategy for enhancing the oral delivery of peptide therapeutics, a long-standing challenge in pharmacology. By repurposing BBI, traditionally seen as an antinutrition…
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obe…
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding sugg…
These preliminary findings are highly significant as they suggest semaglutide could be a viable pharmacologic option for adolescents battling MASLD, a condition currently lacking approved treatments. The observed impr…
This systematic review provides compelling evidence that GLP1RAs offer a crucial therapeutic strategy for improving cardiovascular outcomes in a high-risk population previously less studied: obese individuals with ASC…
This study provides compelling economic evidence that semaglutide 2.4 mg is a highly cost-effective treatment option for obese patients with MASH in Italy. These findings are crucial for health policy makers and payer…
This real-world evidence strongly supports the significant benefits of GLP-1 RAs not only for metabolic control but also for dramatically improving the daily lives of patients with type 2 diabetes and obesity. The obs…
This post hoc analysis provides crucial insights, suggesting that semaglutide's cardiovascular protective effects are robust and extend beyond its weight-reducing capabilities. This finding reinforces the drug's value…
This study provides compelling in vitro evidence that semaglutide may offer a novel therapeutic strategy for osteoarthritis by directly modulating chondrocyte senescence and inflammation. The finding that semaglutide …
This study highlights that for oral semaglutide users, simply increasing the dose may not be the most effective strategy for all outcomes. Personalized dosing based on estimated exposure could optimize weight loss and…
This Phase 3 trial is pivotal for the future of Type 2 Diabetes management, potentially introducing a new, highly effective oral GLP-1R agonist. If Orforglipron demonstrates comparable or superior efficacy and a favor…
This summary underscores that semaglutide offers more than just weight reduction; it significantly enhances the quality of life for people living with obesity. Recognizing these broader benefits is crucial for healthc…
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findin…
This study is critically important for enhancing patient safety during surgical procedures for individuals using GLP-1 RAs. The findings will directly inform updated preoperative fasting guidelines, potentially preven…
This trial design aims to rigorously assess the additive benefit of semaglutide 2.4 mg when combined with a structured lifestyle intervention for weight management. If successful, the findings would further solidify s…
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in w…
This real-world data underscores the substantial weight-loss benefits of GLP-1 RAs, particularly tirzepatide, in patients with rheumatic and musculoskeletal diseases, a population often challenged by weight management…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
The persistent cognitive dysfunction in Major Depressive Disorder (MDD) represents a significant burden for patients, often not adequately addressed by standard antidepressants. Semaglutide, a GLP-1 receptor agonist (…
This study is significant because it explores a novel application of GLP-1 receptor agonists beyond their established roles in diabetes and obesity, potentially positioning them as tools for proactive health optimizat…
This study is crucial for advancing personalized medicine in Type 2 Diabetes management. By comparing Semaglutide (a GLP-1 receptor agonist that enhances insulin secretion and reduces appetite) and Dapagliflozin (an S…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The introduction of resmetirom and the proven efficacy of semaglutide represent a revolutionary shift in the treatment paradigm for MASH, moving beyond solely lifestyle interventions. These drugs offer the first speci…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
The potential findings from this study could significantly advance our understanding of Semaglutide's role in the long-term management of Type 2 Diabetes, particularly concerning the critical challenge of preventing w…